



Fig. S2. The ERK inhibitor, GDC0994, combined with erlotinib or afatinib synergistically decreases the survival of osimertinib-resistant cell lines. The given cell lines plated in 96-well plates were exposed to the indicated concentrations of GDC0994 (GDC) alone, erlotinib (Erl) or afatinib (Afa) alone or their respective combinations. After 3 days, cell numbers were estimated using the SRB assay. The data are means \pm SDs of four replicate determinations. The numbers inside the graphs are CIs for the given combinations.